Article | Published:

FLT3 internal tandem duplication does not impact prognosis after haploidentical allogeneic hematopoietic stem cell transplantation in AML patients

Bone Marrow Transplantation (2019) | Download Citation


Acute myelogenous leukemia (AML) patients with fetal liver tyrosine kinase 3 (FLT3) internal tandem duplications (ITDs) have poor prognoses if treated with chemotherapy only, primarily as they experience increased relapse rates. To determine whether this alteration also affects outcomes after haploidentical donor (HID) allogeneic hematopoietic stem cell transplantation (allo-HSCT), we compared 334 consecutive FLT3-ITD-positive vs -negative patients with AML (other than acute promyelocytic leukemia) who underwent HID-HSCT. FLT3-ITD was detected in 39 of 334 patients (11.7%). The 2-year relapse rates for FLT3-ITD-positive and -negative patients were 16% and 17%, respectively (P = 0.774). The 3-year disease-free survival (DFS) rates for FLT3-ITD-positive and -negative patients were 74% (95% confidence interval [CI]: 64–81) and 73% (95% CI: 70–81), respectively; P = 0.872); while the 3-year overall survival (OS) rates were 72% (95% CI: 67–81) and 77% (95% CI: 72–84), respectively (P = 0.862). FLT3-ITD mutation had no influence on non-relapse mortality (NRM 15% vs 14%, P = 0.463). Multivariate analyses showed that disease status at HSCT and white blood cell count at diagnosis were independent risk factors associated with relapse, DFS, and OS. In conclusion, FLT3 mutation status has no impact on outcomes after HID-HSCT in patients with AML. HID-HSCT is therefore a valid option for AML patients with FLT3-ITD mutation.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Additional information

Publisher’s note: Springer Nature remains neutral with regard to jurisdictional claims in published maps and institutional affiliations.


  1. 1.

    Nakao M, Yokota S, Iwai T, Kaneko H, Horiike S, Kashima K, et al. Internal tandem duplication of the flt3 gene found in acute myeloid leukemia. Leukemia. 1996;10:1911–8.

  2. 2.

    Naoe T, Kiyoi H. Normal and oncogenic FLT3. Cell Mol Life Sci. 2004;61:2932–8.

  3. 3.

    Kiyoi H, Yanada M, Ozekia K. Clinical significance of FLT3 in leukemia. Int J Hematol. 2005;82:85–92.

  4. 4.

    Yanada M, Matsuo K, Suzuki T, Kiyoi H, Naoe T. Prognostic significance of FLT3 internal tandem duplication and tyrosine kinase domain mutations for acute myeloid leukemia: a meta analysis. Leukemia. 2005;19:1345–9.

  5. 5.

    Fröhling S, Schlenk RF, Breitruck J, Benner A, Kreitmeier S, Tobis K. et al. Prognostic significance of activating FLT3 mutations in younger adults (16 to 60 years) with acute myeloid leukemia and normal cytogenetics: a study of the AML Study Group Ulm. Blood. 2002;100:4372–80.

  6. 6.

    Marcucci G, Haferlach T, Döhner H. Molecular genetics of adult acute myeloid leukemia: prognostic and therapeutic implications. J Clin Oncol. 2011;29:475–86.

  7. 7.

    Bornhäuser M, Illmer T, Schaich M, Soucek S, Ehninger G, Thiede C, et al. Improved outcome after stem-cell transplantation in FLT3/ITD positive AML. Blood. 2007;109:2265–6.

  8. 8.

    Morra E, Barosi G, Bosi A, Ferrara F, Locatelli F, Marchetti M, et al. Clinical management of primary non-acute promyelocytic leukemia acute myeloid leukemia: practice guidelines by the Italian Society of Hematology, the Italian Society of Experimental Hematology, and the Italian Group for Bone Marrow Transplantation. Haematologica. 2009;94:102–12.

  9. 9.

    Lin PH, Lin CC, Yang HI, Li LY, Bai LY, Chiu CF, et al. Prognostic impact of allogeneie hematopoietic stem cell transplantation for acute myeloid leukemia patients with internal tandem duplication of FLT3. Leuk Res. 2013;37:287–92.

  10. 10.

    Wang Y, Liu QF, Xu LP, Liu KY, Zhang XH, Ma X, et al. Haploidentical vs identical-sibling transplant for AML in remission: a multicenter, prospective study. Blood. 2015;125:3956–62.

  11. 11.

    Xiao-Jun H, Lan-Ping X, Kai-Yan L, Dai-Hong L, Yu W, Huan C, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res. 2009;15:4777–83.

  12. 12.

    Chou SC, Tang JL, Hou HA, Chou WC, Hu FC, Chen CY, et al. Prognostic implication of gene mutations on overall survival in the adult acute myeloid leukemia patients receiving or not receiving allogeneic hematopoietic stem cell transplantations. Leuk Res. 2014;38:1278–84.

  13. 13.

    Brunet S, Labopin M, Esteve J, Cornelissen J, Socié G, Iori AP, et al. Impact of FLT3 internal tandem duplication on the outcome of related and unrelated hematopoietic transplantation for adult acute myeloid leukemia in first remission: a retrospective analysis. J Clin Oncol. 2012;30:735–41.

  14. 14.

    Schmid C, Labopin M, Socié G, Daguindau E, Volin L, Huynh A, et al. Outcome of patients with distinct molecular genotypes and cytogenetically normal AML after allogeneic transplantation. Blood. 2015;126:2062–9.

  15. 15.

    Song Y, Magenau J, Li Y, Braun T, Chang L, Bixby D, et al. FLT3 mutational status is an independent risk factor for adverse outcomes after allogeneic transplantation in AML. Bone Marrow Transplant. 2016;51:511–20.

  16. 16.

    Sengsayadeth SM, Jagasia M, Engelhardt BG, Kassim A, Strickland SA, Goodman S, et al. Allo-SCT for high-risk AML-CR1 in the molecular era: impact of FLT3/ITD outweighs the conventional markers. Bone Marrow Transplant. 2012;47:1535–7.

  17. 17.

    Deol A, Sengsayadeth S, Ahn KW, Wang HL, Aljurf M, Antin JH, et al. Does FLT3 mutation impact survival after hematopoietic stem cell transplantation for acute myeloid leukemia? A Center for International Blood and Marrow Transplant Research (CIBMTR) analysis. Cancer. 2016;122:3005–14.

  18. 18.

    Canaani J, Labopin M, Huang XJ, Arcese W, Ciceri F, Blaise D, et al. T-cell replete haploidentical stem cell transplantation attenuates the prognostic impact of FLT3-ITD in acute myeloid leukemia: a report from the Acute Leukemia Working Party of the European Society for Blood and Marrow Transplantation. Am J Hematol. 2018;93:736–44.

  19. 19.

    Kiyoi H, Naoe T, Nakano Y, Yokota S, Minami S, Miyawaki S, et al. Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood. 1999;93:3074–80.

  20. 20.

    Wang Y, Liu DH, Liu KY, Xu LP, Zhang XH, Han W, et al. Long-term follow-up of haploidentical hematopoietic stem cell transplantation without in vitro T cell depletion for the treatment of leukemia: nine years of experience at a single center. Cancer. 2013;119:978–85.

  21. 21.

    Zhao XS, Jin S, Zhu HH, Xu LP, Liu DH, Chen H, et al. Wilms’ tumor gene 1 expression: an independent acute leukemia prognostic indicator following allogeneic hematopoietic SCT. Bone Marrow Transplant. 2012;47:499–507.

  22. 22.

    Zhao XS, Yan CH, Liu DH, Xu LP, Liu YR, Liu KY, et al. Combined use of WT1 and flow cytometry monitoring can promote sensitivity of predicting relapse after allogeneic HSCT without affecting specificity. Ann Hematol. 2013;92:1111–9.

  23. 23.

    Yan CH, Liu DH, Liu KY, Xu LP, Liu YR, Chen H, et al. Risk stratification directed donor lymphocyte infusion could reduce relapse of standard-risk acute leukemia patients after allogeneic hematopoietic stem cell transplantation. Blood. 2012;119:3256–62.

  24. 24.

    Yan CH, Wang JZ, Liu DH, Xu LP, Chen H, Liu KY, et al. Chemotherapy followed by modified donor lymphocyte infusion as a treatment for relapsed acute leukemia after haploidentical hematopoietic stem cell transplantation without in vitro T-cell depletion: superior outcomes compared with chemotherapy alone and an analysis of prognostic factors. Eur J Haematol. 2013;91:304–14.

  25. 25.

    Gale RE, Hills R, Kottaridis PD, Srirangan S, Wheatley K, Burnett AK, et al. No evidence that FLT3 status should be considered as an indicator for transplantation in acute myeloid leukemia (AML): an analysis of 1135 patients, excluding acute promyelocytic leukemia, from the UK MRC AML10 and 12 trials. Blood. 2005;106:3658–65.

  26. 26.

    Sullivan KM, Weiden PL, Storb R, Witherspoon RP, Fefer A, Fisher L, et al. Influence of acute and chronic graft-versus-host disease on relapse and survival after bone marrow transplantation from HLA-identical siblings as treatment of acute and chronic leukemia. Blood. 1989;73:1720–8.

  27. 27.

    Weisdorf D, Zhang MJ, Arora M, Horowitz MM, Rizzo JD, Eapen M. Graft-versus-host disease induced graft-versus-leukemia effect: greater impact on relapse and disease-free survival after reduced intensity conditioning. Biol Blood Marrow Transplant. 2012;18:1727–33.

  28. 28.

    Mo XD, Xu LP, Zhang XH, Liu DH, Wang Y, Chen H, et al. Chronic GVHD induced GVL effect after unmanipulated haploidentical hematopoietic SCT for AML and myelodysplastic syndrome. Bone Transplant. 2015;50:127–33.

  29. 29.

    Huang XJ, Xu LP, Liu KY, Liu DH, Wang Y, Chen H, et al. Partially matched related donor transplantation can achieve outcomes comparable with unrelated donor transplantation for patients with hematologic malignancies. Clin Cancer Res. 2009;15:4777–83.

  30. 30.

    Mo XD, Zhang XH, Xu LP, Wang Y, Yan CH, Chen H, et al. Interferon-α: a potentially effective treatment for minimal residual disease in acute leukemia/myelodysplastic syndrome after allogeneic hematopoietic stem cell transplantation. Biol Blood Marrow Transplant. 2015;21:1939–47.

  31. 31.

    Huang XJ, Liu DH, Liu KY, Xu LP, Chen H, Han W. Donor lymphocyte infusion for the treatment of leukemia relapse after HLA-mismatched/haplo-identical T-cell-replete hematopoietic stem cell transplantation. Haematologica. 2007;92:414–7.

  32. 32.

    Alyea EP, Kim HT, Ho V, Cutler C, Gribben J, DeAngelo DJ, et al. Comparative outcome of nonmyeloablative and myeloablative allogeneic hematopoietic cell transplantation for patients older than 50 years of age. Blood. 2005;105:1810–4.

  33. 33.

    Aoudjhane M, Labopin M, Gorin NC, Shimoni A, Ruutu T, Kolb HJ, et al. Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblasticleukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT). Leukemia. 2005;19:2304–12.

  34. 34.

    Rubio MT, Savani BN, Labopin M, Piemontese S, Polge E, Ciceri F, et al. Impact of conditioning intensity in T-replete haplo-identical stem cell transplantation for acute leukemia: a report from the acute leukemia working party of the EBMT. J Hematol Oncol. 2016;9:25. 10.1186/s13045-016-0248-3

  35. 35.

    Rizzieri DA, Koh LP, Long GD, Gasparetto C, Sullivan KM, Horwitz M, et al. Partially matched, nonmyeloablative allogeneic transplantation: clinical outcomes and immune reconstitution. J Clin Oncol. 2007;25:690–7.

  36. 36.

    RF Schlenk, Döhner, Krauter K, Fröhling J, Corbacioglu S, BullingerL A, et al. German-Austrian Acute Myeloid Leukemia Study Group. Mutations and treatment outcome in cytogenetically normal acute myeloid leukemia. N Engl J Med. 2008;358:1909–18.

Download references

Author information


  1. Peking University People’s Hospital, Peking University Institute of Hematology, Beijing, P.R. China

    • Yuan-Yuan Zhang
    • , Xiao-Dong Mo
    • , Xiao-Hui Zhang
    • , Lan-Ping Xu
    • , Yu Wang
    • , Chen-Hua Yan
    • , Huan Chen
    • , Yu-Hong Chen
    • , Wei Han
    • , Feng-Rong Wang
    • , Jing-Zhi Wang
    • , Yu-Qian Sun
    • , Kai-Yan Liu
    •  & Xiao-Jun Huang
  2. Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation for the Treatment of Hematological Diseases, Beijing, P.R. China

    • Yuan-Yuan Zhang
    • , Xiao-Dong Mo
    • , Xiao-Hui Zhang
    • , Lan-Ping Xu
    • , Yu Wang
    • , Chen-Hua Yan
    • , Huan Chen
    • , Yu-Hong Chen
    • , Wei Han
    • , Feng-Rong Wang
    • , Jing-Zhi Wang
    • , Yu-Qian Sun
    • , Kai-Yan Liu
    •  & Xiao-Jun Huang


  1. Search for Yuan-Yuan Zhang in:

  2. Search for Xiao-Dong Mo in:

  3. Search for Xiao-Hui Zhang in:

  4. Search for Lan-Ping Xu in:

  5. Search for Yu Wang in:

  6. Search for Chen-Hua Yan in:

  7. Search for Huan Chen in:

  8. Search for Yu-Hong Chen in:

  9. Search for Wei Han in:

  10. Search for Feng-Rong Wang in:

  11. Search for Jing-Zhi Wang in:

  12. Search for Yu-Qian Sun in:

  13. Search for Kai-Yan Liu in:

  14. Search for Xiao-Jun Huang in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Xiao-Jun Huang.

About this article

Publication history